8-KMaterial AgreementsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Material Agreement (Nov 9, 2006)

Filed November 9, 2006For Securities:ABT

Summary

Abbott Laboratories (ABT) has announced a significant strategic move through the entry into a definitive merger agreement with Kos Pharmaceuticals, Inc. This 8-K filing details an agreement for Abbott, via its subsidiary Parthenon Acquisition Corp., to commence a tender offer to acquire all outstanding Kos shares for $78 per share in cash. This acquisition is poised to expand Abbott's presence in the pharmaceutical sector, particularly through Kos's established product portfolio. The deal structure includes a tender offer followed by a merger, with key shareholders of Kos, including the Jaharis family, having committed to tender a substantial portion of their shares, thereby assuring a significant portion of the required tender. Additionally, Abbott will acquire Kos Investments, Inc., a significant shareholder in Kos Pharmaceuticals, further solidifying the transaction. This move signals Abbott's intent to pursue growth through strategic acquisitions in the healthcare industry.

Key Highlights

  • 1Abbott Laboratories is acquiring Kos Pharmaceuticals, Inc. for $78 per share in cash.
  • 2The transaction will be executed through a tender offer followed by a merger.
  • 3Key Kos shareholders, including the Jaharis family (owning approx. 35%), have committed to tender their shares.
  • 4Abbott will also acquire Kos Investments, Inc., which owns approximately 18% of Kos Pharmaceuticals.
  • 5The acquisition is subject to customary closing conditions, including antitrust approval (Hart-Scott-Rodino Act).
  • 6The agreement includes standard representations, warranties, and covenants from both parties.
  • 7Abbott issued a press release on November 6, 2006, announcing the execution of the merger agreement.

Frequently Asked Questions

This 8-K filing announces Abbott Laboratories' entry into a material definitive agreement to acquire Kos Pharmaceuticals, Inc. It details the terms of the proposed acquisition, including the tender offer price and structure.

While specific financial projections are not detailed in this 8-K, the acquisition of Kos Pharmaceuticals for $78 per share in cash represents a significant capital outlay for Abbott. Investors should look to future filings and management commentary for details on the expected impact on earnings, revenue synergies, and the integration costs.

The filing notes that the tender offer and merger are subject to customary closing conditions, including antitrust review under the Hart-Scott-Rodino Act. The success of the tender offer is also conditioned on acquiring a majority of Kos shares, though this is largely assured due to significant shareholder commitments. Abbott's forward-looking statements caution that actual results could differ materially due to various risks and uncertainties.

The tender offer had not yet commenced at the time of this filing. Abbott will file a tender offer statement with the SEC. Investors and Kos security holders are advised to read the tender offer statement, offer to purchase, and related documents, as well as Kos's solicitation/recommendation statement, which will be available on the SEC's website (www.sec.gov).